Canada markets closed

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1500-0.0800 (-3.59%)
At close: 4:00PM EDT
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Solid Biosciences is up 9.33% to 2.46
  • Y
    Yahoo Finance Insights
    Solid Biosciences is down 9.80% to 2.07
  • H
    Happ
    I started following "lionstock-aletrs” (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • Y
    Yahoo Finance Insights
    Solid Biosciences is down 10.49% to 2.73
  • B
    Billy
    lifting of trial hold will double or triple the price, but is it coming?, and if so, when?
  • M
    Michael
    My guess is FDA wants to know if it is effective and what is lowest viral load that can be effective. I believe it has been proven to be effective and it will be approved with the only question “ approved dose “ That my opinion. It will trade at 5-6 in 2020
  • B
    Billy
    ouch, news out, still on clinical hold, more info needed by fda
  • B
    Bloodmoon
    Ouch is right .
  • c
    claudio
    Is there any hope for this company ?
  • B
    Bloodmoon
    52 week low will be coming. buy it on the dip
  • W
    WorldWasFlat
    Sorry, this is going back up. All the stop losses are taken out. Logically speaking, they are on their path to execution. The results are as expected. Slowly but surely, this will rise. Give it some time. Don't panic sell. Buy low sell high--a sage advise.
  • m
    metoo
    ** SVB Leerink expects the upcoming data readout from a study testing SLDB's experimental gene therapy for muscle-wasting Duchenne muscular dystrophy (DMD), to serve as a springboard for co, if it reports positive data in 2H 2019

    ** Upgrades stock to 'outperform' from 'market perform'; hikes PT to $15 from $8

    ** In May, co said a patient in the treatment group of its early stage DMD trial was diagnosed with a gastrointestinal infection that was classified as a "serious adverse event unrelated to study drug"

    ** Brokerage says SLDB has a good risk/reward profile heading into the next data readout for the experimental DMD gene therapy, SGT-001, given changes in the study's protocol to improve outcomes and speed up enrollment

    ** Says SLDB's potential to scale-up and switch to commercial scale manufacturing for SGT-001, could also help it catch up with competitor and DMD "group leader" Sarepta Therapeutics
  • K
    Kim
    $SRPT conversation
    Baird Sarepta Therapeutics $SRPT)
    Competitor's $SLDB AAV9 DMD GT Falls Flat, Widening Sarepta's Lead-Based on the totality of the evidence presented to date we believe it is clear that SRP-9001 is safer and more effective vector as compared to the AAV9-based competitors.
  • J
    JUGGERNAUTS
    We are encouraged to continue advancing SGT-001 in the clinic,” said Jorge Quiroz, M.D., Chief Medical Officer of Solid Biosciences. “Based on our preclinical data, we expect that increased doses of SGT-001 will achieve higher microdystrophin expression and, with agreement from the study’s Data Safety Monitoring Board and the University of Florida Institutional Review Board, we have initiated the appropriate activities to dose escalate.”
  • M
    Moshe
    “SGT-001 represents the most advanced dystrophin biology in development for Duchenne,” said Jeffrey Chamberlain, Professor of Neurology and McCaw Endowed Chair in Muscular Dystrophy at the University of Washington School of Medicine. “SGT-001’s novel construct was specifically selected to drive expression of the drug’s unique microdystrophin in cardiac and skeletal muscle, critical not only to mobility, but also to cardiac and pulmonary function. Continued evaluation of SGT-001 is essential to determine the ultimate clinical benefits that SGT-001 may provide for patients.”
  • K
    Kim
    $SRPT conversation
    BTIG raising $SRPT price target to $190 following the PPMD conference...
    Anyone who watched the conference understood who is clearly the "winner in the room"
    Feels like $SRPT is 2 years ahead of $PFE & $SLDB is even way back!
  • D
    DavidO
    “The data from these patients show SGT-001 microdystrophin expression and associated neuronal nitric oxide synthase (nNOS) function, providing evidence that SGT-001 has the potential to result in therapeutic benefit for patients with Duchenne.”
  • P
    Pitstainer2
    It’s hard to survive a clinical hold but $ARWR was able to do it because they had a broad pipeline and platform on deck after the strike out. ARWR is developing muscle targeting version of TRiM, likely going after DMD. Give them a look as you reassess your portfolio allocation. Thank you.
  • K
    Ken
    This is a great stock! It will be $50 by end of year! Congrats to all of us who jumped in at around $8...nearly 300% up in a matter of a few months.
  • D
    David
    What was going on with SLDB when it was at the 52 week high of $32.85? How does our situation now compare to then? Please give a quick summary of the news and events timeline please.